These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 24566015)

  • 1. Epidemiological analysis of progression-free survival (PFS) and overall survival (OS) in non-small-cell lung cancer patients in Republic of Macedonia.
    Risteski M; Crvenkova S; Atanasov Z; Isjanovska R
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2013; 34(3):49-61. PubMed ID: 24566015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival results and prognostic factors in T4 N0-3 non-small cell lung cancer patients according to the AJCC 7th edition staging system.
    Arslan D; Bozcuk H; Gunduz S; Tural D; Tattli AM; Uysal M; Goksu SS; Bassorgun Cİ; Koral L; Coskun HS; Ozdogan M; Savas B
    Asian Pac J Cancer Prev; 2014; 15(6):2465-72. PubMed ID: 24761848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.
    Yang KL; Chang YC; Ko HL; Chi MS; Wang HE; Hsu PS; Lin CC; Yeh DY; Kao SJ; Jiang JS; Chi KH
    Clin Lung Cancer; 2016 Nov; 17(6):550-557. PubMed ID: 27378175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival of patients with advanced non-small-cell lung cancer at Ubon Ratchathani Cancer Center, Thailand.
    Srisam-Ang K; Podhipak A; Narksawat K; Supaattagorn P; Tipayamongkholgul M
    Southeast Asian J Trop Med Public Health; 2005 Jul; 36(4):994-1006. PubMed ID: 16295558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Value of surgery for stage IIIa non-small cell lung cancer].
    Liu H; Wang M; Hu K; Xu Y; Ma M; Zhong W; Zhao J; Li L; Wang H
    Zhongguo Fei Ai Za Zhi; 2013 Dec; 16(12):639-45. PubMed ID: 24345488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upfront surgery as first-line therapy in selected patients with stage IIIA non-small cell lung cancer.
    Zheng D; Ye T; Hu H; Zhang Y; Sun Y; Xiang J; Chen H
    J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1814-1822.e4. PubMed ID: 29221745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990.
    Wakelee HA; Bernardo P; Johnson DH; Schiller JH
    Cancer; 2006 May; 106(10):2208-17. PubMed ID: 16604529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Presentation and stage-specific outcomes of lifelong never-smokers with non-small cell lung cancer (NSCLC).
    Subramanian J; Velcheti V; Gao F; Govindan R
    J Thorac Oncol; 2007 Sep; 2(9):827-30. PubMed ID: 17805060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome predictors for 143 patients with superior sulcus tumors treated by multidisciplinary approach at the University of Texas M. D. Anderson Cancer Center.
    Komaki R; Roth JA; Walsh GL; Putnam JB; Vaporciyan A; Lee JS; Fossella FV; Chasen M; Delclos ME; Cox JD
    Int J Radiat Oncol Biol Phys; 2000 Sep; 48(2):347-54. PubMed ID: 10974447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
    Reck M; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Gann CN; Barrueco J; Gaschler-Markefski B; Novello S;
    Lancet Oncol; 2014 Feb; 15(2):143-55. PubMed ID: 24411639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment patterns and outcomes in patients with non-squamous advanced non-small cell lung cancer receiving second-line treatment in a community-based oncology network.
    Pan IW; Mallick R; Dhanda R; Nadler E
    Lung Cancer; 2013 Dec; 82(3):469-76. PubMed ID: 24396885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort.
    Okamoto I; Morita S; Tashiro N; Imamura F; Inoue A; Seto T; Yamamoto N; Ohe Y; Nakagawa K; Fukuoka M
    Lung Cancer; 2018 Mar; 117():14-19. PubMed ID: 29496250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival and Racial Differences of Non-Small Cell Lung Cancer in the United States Military.
    Brzezniak C; Satram-Hoang S; Goertz HP; Reyes C; Gunuganti A; Gallagher C; Carter CA
    J Gen Intern Med; 2015 Oct; 30(10):1406-12. PubMed ID: 25805503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
    Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
    Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lung cancer in women, a different disease: survival differences by sex in Turkey.
    Ulas A; Tokluoglu S; Kos M; Silay K; Akinci S; Oksuzoglu B; Alkis N
    Asian Pac J Cancer Prev; 2015; 16(2):815-22. PubMed ID: 25684531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypofractionated Image-guided Radiation Therapy (3Gy/fraction) in Patients Affected by Inoperable Advanced-stage Non-small Cell Lung Cancer After Long-term Follow-up.
    Agolli L; Valeriani M; Bracci S; Nicosia L; DE Sanctis V; Enrici RM; Osti MF
    Anticancer Res; 2015 Oct; 35(10):5693-700. PubMed ID: 26408745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Evaluation of Durative Transfusion of Endostar Combined with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer.
    Li X; Gu G; Soliman F; Sanders AJ; Wang X; Liu C
    Chemotherapy; 2018; 63(4):214-219. PubMed ID: 30347389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of paclitaxel (day 1 and 8) and carboplatin given on every three weeks in advanced (stage III-IV) non-small cell lung cancer.
    Yumuk PF; Turhal NS; Gumus M; Hatabay NF; Turken O; Ozkan A; Salepci T; Aliustaoglu M; Ahiskali R
    BMC Cancer; 2005 Jan; 5():10. PubMed ID: 15667664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment outcome of locally advanced stage IIIA/B lung cancer].
    Cicenas S; Zaliene A; Atkocius V
    Medicina (Kaunas); 2009; 45(6):452-9. PubMed ID: 19605965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of Nivolumab versus Docetaxel as Second-Line Treatment in Non-Small Cell Lung Cancer Patients in Clinical Practice.
    Calpe-Armero P; Ferriols-Lisart R; Ferriols-Lisart F; Pérez-Pitarch A
    Chemotherapy; 2017; 62(6):374-380. PubMed ID: 29045938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.